Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Hexetidine: Translating Oral Antimicrobial Evidence
2026-09-26
Hexetidine (NSC-17764) offers a useful model for studying oral antisepsis, but its broad activity and non-specific mechanism make assay design and clinical context essential. This article connects susceptibility testing and biofilm workflows with the evidence on plaque and gingival inflammation, highlighting how translational teams can distinguish promising laboratory signals from claims the data do not support.
-
Lipo3K Transfection Reagent for Ferroptosis Studies
2026-09-25
Map the OTUD3–SLC7A11 resistance pathway with a practical transfection plan for knockdown, overexpression, and rescue experiments. Lipo3K Transfection Reagent supports DNA, siRNA, and co-transfection workflows, with low-toxicity handling that can help preserve cells for downstream analysis.
-
Aclacinomycin A for rDNA Damage Workflows
2026-09-25
Use Aclacinomycin A to connect topoisomerase-linked DNA stress with apoptosis, while keeping rDNA and PML-nucleolar readouts experimentally testable rather than assumed. This workflow pairs dose-and-time optimization with controls that separate early damage signaling, caspase activity, and later loss of viability.
-
Lisinopril Dihydrate: Beyond ACE Potency
2026-09-24
Lisinopril dihydrate offers a precise entry point into renin–angiotensin system research—but translational confidence depends on separating ACE target engagement from downstream physiology and neighboring peptidase activity. This article outlines an evidence-led strategy for using the compound in cardiovascular and renal models.
-
HPF Workflows for Nanotherapy ROS Validation
2026-09-24
Use HPF to track hydroxyl radical and peroxynitrite-associated signals during oxidative-stress experiments—without mistaking its readout for total ROS or singlet oxygen. This workflow guide shows how to apply hydroxyphenyl fluorescein to copper-based nanotherapy studies, build informative controls, and troubleshoot fluorescence artifacts.
-
From Matrix Biology to siRNA Nanotherapy
2026-09-23
Hyaluronic acid sodium salt is more than a structural matrix material: its viscoelastic biology and formulation role can intersect with RNA delivery. A recent preclinical study of HA-coated siRNA nanoparticles targeting TDRD9 offers a useful case study in how to connect carrier design, immune mechanisms, and translational validation—while keeping the limits of the evidence in view.
-
Anti-Epileptic Drugs and Human PON1 Inhibition
2026-09-23
The reference study evaluated how five anti-epileptic drugs inhibit purified human serum paraoxonase-1 (hPON1) in vitro, combining enzyme purification with concentration-dependent activity and kinetic analyses. Its most important finding was that inhibition varied substantially among drugs, while all tested compounds showed a noncompetitive pattern, highlighting a biochemical interaction that is distinct from their primary neuronal targets.
-
HyperTrap Heparin HP Column for Stemness Workflows
2026-09-22
The HyperTrap Heparin HP Column converts heparin-binding proteins into cleaner, more reproducible inputs for signaling and cell-based assays. Its fine-particle HyperChrom Heparin HP Agarose supports flexible workflows spanning growth-factor preparation, coagulation-protein purification, and nucleic-acid-associated enzyme enrichment.
-
Thrombin B Chain Fragment: Mechanism and Uses
2026-09-22
Thrombin is a trypsin-like serine protease encoded by F2, but A1057 is a defined 19-residue B-chain fragment rather than full-length active enzyme. The product is a high-purity peptide reagent for identity, binding, and assay-development workflows, while fibrinogen to fibrin conversion and platelet activation require validated intact thrombin systems.
-
Thrombin B Chain Fragment: Assay Guide
2026-09-21
This scenario-led guide explains how to evaluate thrombin-related effects in cell viability, proliferation, cytotoxicity, and fibrin-matrix workflows. It positions Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens] (SKU A1057) as a defined, analytically characterized test article while separating product facts from assay-specific recommendations.
-
RSL3 Workflows for GPX4-Driven Ferroptosis
2026-09-21
RSL3 is a practical glutathione peroxidase 4 inhibitor for separating ferroptotic cell death from simple growth arrest. This workflow combines dose-response design, time-resolved viability measurements, lipid-peroxidation validation, and rescue controls for cancer models.
-
Thrombin B Chain Fragment: Assay Logic
2026-09-20
Explore how Thrombin B Chain Fragment A1057 supports identity-aware coagulation and protease assay design. This guide distinguishes sequence-defined peptide measurements from intact thrombin activity and applies lessons from selective 3CLpro inhibitor screening.
-
Ciprofloxacin hydrochloride: Research Workflows
2026-09-19
Turn a classic fluoroquinolone antibiotic into a quantitative research tool for bacterial growth, DNA-damage, and antibiotic-combination studies. This guide combines practical handling advice with single-cell assay design, troubleshooting, and carefully bounded translational applications.
-
HRP Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-18
HRP Goat Anti-Rabbit IgG (H+L) Antibody, SKU K1223, provides HRP-based detection of rabbit IgG primary antibodies in ELISA, Western blotting, IHC, and IC workflows. It is a research-use reagent only; because no fixed working dilution or directly matched paper evidence is provided, assay-specific titration and controls are required.
-
H 89 2HCl: PKA Signaling in Osteoclast Assays
2026-09-18
H 89 2HCl provides a practical pharmacological perturbation for testing whether cAMP/PKA/CREB signaling contributes to osteoclast differentiation and other phosphorylation-dependent phenotypes. Its value is greatest when paired with cAMP measurements, rescue experiments, viability controls, and orthogonal pathway validation because cellular concentrations can exceed its biochemical selectivity window.